"The merger of Ranbaxy into Sun Pharma pursuant to the scheme will result in Sun Pharma indirectly acquiring 46.79 per cent of the voting rights held by Ranbaxy in, and control over Zenotech, although the acquisition of voting rights in or control over the target company is not the objective of the primary acquisition," the filing said.